ARCA Biopharma – Precision Medicine | 合法醫療器材資訊網

rNAPc2 (AB201) is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral ... Read More

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics ... Read More

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2. 08.04.2021. Read More

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th · ARCA biopharma Announces Submission of PCT Patent Application for the Treatment ... Read More

ARCA biopharma, Inc.(ABIO.US)為一家生物製藥公司，專注於開發新基因靶向療法治療心血管疾病。它的主要候選產品是Gencaro，藥理獨特的β受體阻滯劑和溫和的血管擴張劑用以 ... Read More

ARCA biopharma, Inc. | 751 followers on LinkedIn. Pharmacogenetic Precision Medicine for Cardiovascular Diseases | ARCA was founded on the belief that a ... Read More

Find the latest ARCA biopharma, Inc. (ABIO) stock quote, history, news and other vital information to help you with your stock trading and investing. Read More

ARCA biopharma, Inc.(ABIO.US)為一家生物製藥公司，專注於開發新基因靶向療法治療心血管疾病。它的主要候選產品是Gencaro，藥理獨特的β受體阻滯劑和溫和的血管擴張劑 ... Read More

ARCA biopharma Inc. (NASDAQ: ABIO) is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine ... Read More